Compare Johnson & Johnson (JNJ) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Lufax Holding Ltd — how do they compare? Johnson & Johnson trades at $260.72 (market cap $618.09B), while Lufax Holding Ltd trades at $0.99 (market cap $982.89M). The key difference: Johnson & Johnson is far larger — about 628.8× Lufax Holding Ltd's market cap, and Johnson & Johnson pays a 2.09% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Lufax Holding Ltd for 13 Days on average.
| JNJ | LU | |
|---|---|---|
Market Cap | $618.09B | $982.89M |
Volume | 6,050,983 | 3,323,384 |
Sector | Health | Financials |
52-Week High | $278.43 | $3.93 |
52-Week Low | $186.00 | $0.95 |
Typical Hold Time | 129 Days | 13 Days |
Enterprise Value | $646.37B | $58.81B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Lufax (LU) trades at $0.986, up 0.47% on the day, but shows significant fundamental challenges with consecutive quarterly losses and declining revenue. The company recently completed a 10:1 reverse stock split and faces bearish technical signals despite some oversold RSI readings. Analyst sentiment remains predominantly bullish with 69% buy ratings, pointing to potential value in the depressed valuation multiples.
The investment case hinges on Lufax's deep value proposition trading at 0.07x book value, but requires successful navigation of regulatory headwinds and return to profitability. Key risks include persistent net losses, Chinese regulatory uncertainty, and declining top-line performance that could pressure the stock further despite strong institutional backing from parent company Ping An.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
